Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
186 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Wounds - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H1 2017, provides an overview of the Wounds (Dermatology) pipeline landscape. Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 58, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 7 molecules, respectively. Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology). - The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Wounds - Overview 9 Wounds - Therapeutics Development 10 Pipeline Overview 10 Pipeline by Companies 11 Pipeline by Universities/Institutes 16 Products under Development by Companies 18 Products under Development by Universities/Institutes 22 Wounds - Therapeutics Assessment 23 Assessment by Target 23 Assessment by Mechanism of Action 26 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Wounds - Companies Involved in Therapeutics Development 33 AlgiPharma AS 33 Alliance Pharma Plc 33 AmpliPhi Biosciences Corp 33 AndroScience Corp 34 Anterogen Co Ltd 34 Aridis Pharmaceuticals LLC 35 Beech Tree Labs Inc 35 Bio3 Research Srl 35 Biotec Pharmacon ASA 36 Blueberry Therapeutics Ltd 36 Cellphire Inc 36 Chiesi Farmaceutici SpA 37 CorMedix Inc 37 Dermala Inc 38 Destiny Pharma Ltd 38 Escape Therapeutics Inc 38 EyeGene Inc 39 FibroGen Inc 39 Foresee Pharmaceuticals LLC 40 Gene Signal International SA 40 GlaxoSmithKline Plc 40 IC-MedTech Inc 41 Living Cell Technologies Ltd 41 Madam Therapeutics BV 42 miRagen Therapeutics Inc 42 NatureWise Biotech & Medicals Corp 43 Novan Inc 43 Octapharma AG 44 Omeros Corp 44 Osiris Therapeutics Inc 44 Pacific Northwest Biotechnology LLC 45 ProMetic Life Sciences Inc 45 RMB-Research GmbH 46 RXi Pharmaceuticals Corp 46 SomaGenics Inc 47 Stratatech Corp 47 Synedgen Inc 47 Thesan Pharmaceuticals Inc 48 Topadur Pharma AG 48 Traverse Biosciences Inc 48 Tumorend LLC 49 Vascular BioSciences 49 viDA Therapeutics Inc 49 Wounds - Drug Profiles 51 (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 51 A-3APO - Drug Profile 52 ABSA-01 - Drug Profile 54 AGL-110 - Drug Profile 58 ALLO-ASC - Drug Profile 59 AlloGraf - Drug Profile 61 Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile 62 APO-1 - Drug Profile 63 APO-2 - Drug Profile 64 AR-101 - Drug Profile 65 Arginine Butyrate - Drug Profile 66 ARN-077 - Drug Profile 67 ASCJ-9 - Drug Profile 68 AyuV-25 - Drug Profile 70 B-244 - Drug Profile 71 BB-1000 - Drug Profile 73 BDM-I - Drug Profile 74 BTL-slo - Drug Profile 77 CAR Peptide - Drug Profile 79 Cell Therapy for Dermatology and Immunology - Drug Profile 80 CM-101 - Drug Profile 82 CRMD-004 - Drug Profile 83 CTR-2 - Drug Profile 84 daprodustat - Drug Profile 85 DB-2121 - Drug Profile 88 Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile 89 Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile 90 Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 91 EGS-001 - Drug Profile 92 FG-6874 - Drug Profile 93 FP-025 - Drug Profile 94 G-3KL - Drug Profile 95 Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 96 Gene Therapy to Activate HSP60 for Wounds - Drug Profile 97 GS-156 - Drug Profile 98 Human Growth Factor - Drug Profile 99 hVGF - Drug Profile 100 JM-2 CR - Drug Profile 101 LWnt-3a - Drug Profile 102 MG-53 - Drug Profile 103 MMP-26051 - Drug Profile 105 MMP-26052 - Drug Profile 106 molgramostim - Drug Profile 107 Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile 108 MRG-110 - Drug Profile 109 NBM-67 - Drug Profile 110 ND-336 - Drug Profile 111 NTCELL - Drug Profile 112 Oligomer G for Burn Wounds - Drug Profile 117 OTI-1011 - Drug Profile 118 OTI-1502 - Drug Profile 119 P-148 - Drug Profile 120 Panaecin - Drug Profile 121 Peptides for Wounds - Drug Profile 122 Perlecan - Drug Profile 123 PGF - Drug Profile 125 plasminogen (recombinant) - Drug Profile 126 Polysaccharide for Wounds and Scars - Drug Profile 127 Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile 128 Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile 129 Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 130 Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 131 Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile 132 Recombinant Protein to Agonize FGFR2 for Wounds - Drug Profile 133 Recombinant Protein to Agonize NGFR for Wounds - Drug Profile 134 Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 135 Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 136 Recombinant Proteins for Diabetic Wound Healing - Drug Profile 137 RT-1740 - Drug Profile 138 SFR-9X0125 - Drug Profile 139 SG-404 - Drug Profile 140 silver sulfadiazine - Drug Profile 141 Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile 142 Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile 143 Small Molecule to Target LGR6 for Dermatology - Drug Profile 144 Small Molecules for Staphylococcal Infections and Wounds - Drug Profile 145 Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile 146 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 147 Soluble Beta Glucan - Drug Profile 148 Statmicoll - Drug Profile 151 Stm Cell Therapy for Chronic Wounds - Drug Profile 152 Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile 153 Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile 154 Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile 155 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 156 Thrombosomes - Drug Profile 158 Tolecine - Drug Profile 159 TOPN-53 - Drug Profile 160 TRBN-0224 - Drug Profile 161 TWB-103 - Drug Profile 163 V-2248 - Drug Profile 164 VTI-3000 Series - Drug Profile 165 WH-1 - Drug Profile 166 XF-70 - Drug Profile 167 Wounds - Dormant Projects 168 Wounds - Discontinued Products 173 Wounds - Product Development Milestones 174 Featured News & Press Releases 174 Appendix 179 Methodology 179 Coverage 179 Secondary Research 179 Primary Research 179 Expert Panel Validation 179 Contact Us 179 Disclaimer 180
List of Tables
Number of Products under Development for Wounds, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Wounds - Pipeline by AlgiPharma AS, H1 2017 Wounds - Pipeline by Alliance Pharma Plc, H1 2017 Wounds - Pipeline by AmpliPhi Biosciences Corp, H1 2017 Wounds - Pipeline by AndroScience Corp, H1 2017 Wounds - Pipeline by Anterogen Co Ltd, H1 2017 Wounds - Pipeline by Aridis Pharmaceuticals LLC, H1 2017 Wounds - Pipeline by Beech Tree Labs Inc, H1 2017 Wounds - Pipeline by Bio3 Research Srl, H1 2017 Wounds - Pipeline by Biotec Pharmacon ASA, H1 2017 Wounds - Pipeline by Blueberry Therapeutics Ltd, H1 2017 Wounds - Pipeline by Cellphire Inc, H1 2017 Wounds - Pipeline by Chiesi Farmaceutici SpA, H1 2017 Wounds - Pipeline by CorMedix Inc, H1 2017 Wounds - Pipeline by Dermala Inc, H1 2017 Wounds - Pipeline by Destiny Pharma Ltd, H1 2017 Wounds - Pipeline by Escape Therapeutics Inc, H1 2017 Wounds - Pipeline by EyeGene Inc, H1 2017 Wounds - Pipeline by FibroGen Inc, H1 2017 Wounds - Pipeline by Foresee Pharmaceuticals LLC, H1 2017 Wounds - Pipeline by Gene Signal International SA, H1 2017 Wounds - Pipeline by GlaxoSmithKline Plc, H1 2017 Wounds - Pipeline by IC-MedTech Inc, H1 2017 Wounds - Pipeline by Living Cell Technologies Ltd, H1 2017 Wounds - Pipeline by Madam Therapeutics BV, H1 2017 Wounds - Pipeline by miRagen Therapeutics Inc, H1 2017 Wounds - Pipeline by NatureWise Biotech & Medicals Corp, H1 2017 Wounds - Pipeline by Novan Inc, H1 2017 Wounds - Pipeline by Octapharma AG, H1 2017 Wounds - Pipeline by Omeros Corp, H1 2017 Wounds - Pipeline by Osiris Therapeutics Inc, H1 2017 Wounds - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017 Wounds - Pipeline by ProMetic Life Sciences Inc, H1 2017 Wounds - Pipeline by RMB-Research GmbH, H1 2017 Wounds - Pipeline by RXi Pharmaceuticals Corp, H1 2017 Wounds - Pipeline by SomaGenics Inc, H1 2017 Wounds - Pipeline by Stratatech Corp, H1 2017 Wounds - Pipeline by Synedgen Inc, H1 2017 Wounds - Pipeline by Thesan Pharmaceuticals Inc, H1 2017 Wounds - Pipeline by Topadur Pharma AG, H1 2017 Wounds - Pipeline by Traverse Biosciences Inc, H1 2017 Wounds - Pipeline by Tumorend LLC, H1 2017 Wounds - Pipeline by Vascular BioSciences, H1 2017 Wounds - Pipeline by viDA Therapeutics Inc, H1 2017 Wounds - Dormant Projects, H1 2017 Wounds - Dormant Projects, H1 2017 (Contd..1), H1 2017 Wounds - Dormant Projects, H1 2017 (Contd..2), H1 2017 Wounds - Dormant Projects, H1 2017 (Contd..3), H1 2017 Wounds - Dormant Projects, H1 2017 (Contd..4), H1 2017 Wounds - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
